ID   MEC-1
AC   CVCL_1870
SY   MEC1
DR   BTO; BTO:0005913
DR   CLO; CLO_0037181
DR   EFO; EFO_0002231
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03471015
DR   BioSample; SAMN10989555
DR   cancercelllines; CVCL_1870
DR   Cell_Model_Passport; SIDM00001
DR   ChEMBL-Cells; CHEMBL4482990
DR   ChEMBL-Targets; CHEMBL4483257
DR   Cosmic; 1762462
DR   DepMap; ACH-000405
DR   DSMZ; ACC-497
DR   DSMZCellDive; ACC-497
DR   EGA; EGAS00001000978
DR   GDSC; 1330943
DR   GEO; GSM887305
DR   GEO; GSM888381
DR   GEO; GSM1374667
DR   GEO; GSM1670091
DR   IARC_TP53; 28260
DR   IGRhCellID; MEC1
DR   LiGeA; CCLE_715
DR   LINCS_LDP; LCL-1089
DR   PharmacoDB; MEC1_911_2019
DR   Progenetix; CVCL_1870
DR   PubChem_Cell_line; CVCL_1870
DR   Wikidata; Q54904995
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=10071128;
RX   PubMed=20215515;
RX   PubMed=20454443;
RX   PubMed=22460905;
RX   PubMed=23297799;
RX   PubMed=25162594;
RX   PubMed=25877200;
RX   PubMed=28196595;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: ~40 hours (PubMed=10071128; DSMZ=ACC-497).
CC   HLA typing: A*23:01:01,30:01:01; B*13:02:01;18:01:01; C*06:02:01;12:03:01; DPA1*01:03:01;01:03:01; DPB1*04:02:01;02:01:02; DQA1*01:02:01;05:05:01; DQB1*03:01:01;06:02:01; DRA*01:02:02;01:02:03; DRB1*12:01:01;15:01:01 (DSMZCellDive=ACC-497).
CC   Sequence variation: Gene fusion; HGNC; 9476; HTRA1 + HGNC; 23512; R3HCC1L; Name(s)=R3HCC1L-HTRA1 (PubMed=31160637).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Profs*20 (c.949dupC) (c.949_950insC); Zygosity=Homozygous (DepMap).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.9%; Native American=0%; East Asian, North=2.04%; East Asian, South=0%; South Asian=5.76%; European, North=26.14%; European, South=64.15% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): DSMZ; Genomics_Center_BCF_Technion; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D10S1248: 17
ST   D12S391: 24
ST   D13S317: 11,12
ST   D16S539: 9,11
ST   D18S51: 14
ST   D19S433: 12,14
ST   D1S1656: 15,17
ST   D21S11: 27,29
ST   D22S1045: 15,16
ST   D2S1338: 16,19
ST   D2S441: 14
ST   D3S1358: 15,19
ST   D5S818: 10,12
ST   D7S820: 7,11
ST   D8S1179: 13,15
ST   DYS391: 10
ST   FGA: 21,25
ST   Penta D: 11,17
ST   Penta E: 10,12
ST   TH01: 6,8
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C3163; Chronic lymphocytic leukemia
DI   ORDO; Orphanet_67038; B-cell chronic lymphocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1871 ! MEC-2
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 34
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=10071128; DOI=10.1016/S0145-2126(98)00154-4;
RA   Stacchini A., Aragno M., Vallario A., Alfarano A., Circosta P.,
RA   Gottardi D., Faldella A., Rege-Cambrin G., Thunberg U., Nilsson K.,
RA   Caligaris-Cappio F.;
RT   "MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic
RT   leukaemia in prolymphocytoid transformation.";
RL   Leuk. Res. 23:127-136(1999).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20454443; DOI=10.1155/2010/904767;
RA   Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.;
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23297799; DOI=10.3109/10428194.2013.764418;
RA   Myhrinder A.L., Hellqvist E., Bergh A.-C., Jansson M.,
RA   Nilsson K., Hultman P., Jonasson J., Buhl A.M., Pedersen L.B.,
RA   Jurlander J., Klein E., Weit N., Herling M., Rosenquist R., Rosen A.;
RT   "Molecular characterization of neoplastic and normal 'sister'
RT   lymphoblastoid B-cell lines from chronic lymphocytic leukemia.";
RL   Leuk. Lymphoma 54:1769-1779(2013).
//
RX   PubMed=25162594; DOI=10.1371/journal.pone.0106008;
RA   Rasul E., Salamon D., Nagy N., Leveau B., Banati F., Szenthe K.,
RA   Koroknai A., Minarovits J., Klein G., Klein E.;
RT   "The MEC1 and MEC2 lines represent two CLL subclones in different
RT   stages of progression towards prolymphocytic leukemia.";
RL   PLoS ONE 9:E106008-E106008(2014).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//